Live
Endpoints NewsShionogi wins US approval for first pill to prevent Covid following exposureEndpoints News#ASCO: Lilly's plenaries; Incyte's frontline data in lymphomaBioPharma DiveServier buys into muscular dystrophy with potentially $2.7B dealBioWorldASCO 2026: A revolution in pancreatic cancerBioWorldBiggest gainers and losers for May 25-29, 2026Endpoints NewsAgios licenses Oscotec drug; CEPI funds three potential Ebola vaccinesPromega BlogAdvancing Canine Cancer Immunotherapy through One Health Comparative Oncology ResearchEndpoints News#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T updateEndpoints NewsAfter being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingFierceBiotechRallybio swerves past Candid pothole to land deal with cancer drug developer AvenzoFierceBiotechAgios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 studyPharmaVoiceAstraZeneca aims for a new blockbuster run in cardio disease
Roche Media Apr 17, 2026

Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout - Medical Device Network

Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout - Medical Device Network

Body unavailable. Use the original source.